Physician profile
Aaron Becker
NPI 1053575365
$14,086.88
in general payments reported to CMS, 2019-2025
55 companies · $2,504 in 2025
The $2,504 reported for 2025 was more than what 84% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,398 · 2020: $1,144 · 2021: $2,551 · 2022: $2,478 · 2023: $1,829 · 2024: $2,184 · 2025: $2,504.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,401 · Education: $100 · Entertainment: $15.43.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,401.26 |
| Education | $100.06 |
| Entertainment | $15.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $3,230.84 | 2021-2025 | Interstim, Altaviva |
| Boston Scientific Corporation | $906.88 | 2019-2023 | Ams 700 |
| Medtronic USA, INC. | $857.63 | 2019-2020 | |
| Procept Biorobotics Corporation | $828.21 | 2020-2025 | Aquabeam System, Aquabeam Robotic System |
| Endo Pharmaceuticals INC. | $806.09 | 2019-2024 | Xiaflex, Aveed |
| Antares Pharma, INC. | $796.16 | 2019-2025 | Xyosted, Nocdurna, Tlando |
| Sumitomo Pharma America, INC. | $746.24 | 2023-2025 | Gemtesa, Orgovyx |
| Urogen Pharma, INC. | $589.74 | 2021-2025 | Jelmyto |
| Teleflex LLC | $567.24 | 2020-2025 | Urolift |
| Astellas Pharma US INC | $475.89 | 2019-2024 | Myrbetriq, Veozah |
| Janssen Biotech, INC. | $373.87 | 2020-2024 | Erleada |
| Verity Pharmaceuticals INC. | $365.49 | 2024-2025 | Trelstar, Tlando |
| Merck Sharp & Dohme LLC | $271.72 | 2020-2025 | Keytruda, Lynparza, Welireg |
| Myriad Genetic Laboratories, INC. | $243.47 | 2020-2024 | Prolaris |
| Coloplast Corp | $209.46 | 2020-2022 |
Show all 54 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$9,770.18 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aaron Becker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.